BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 19,770,000 shares, an increase of 23.5% from the February 28th total of 16,010,000 shares. Approximately 10.0% of the company’s stock are short sold. Based on an average daily volume of 3,140,000 shares, the short-interest ratio is currently 6.3 days.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BCRX. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.43 on Thursday. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.50. The business has a fifty day moving average price of $8.17 and a 200-day moving average price of $7.82. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.18 and a beta of 1.84.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period in the previous year, the business posted $0.28 EPS. The business’s revenue was up 40.8% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $33,000. Venturi Wealth Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $48,000. KBC Group NV raised its stake in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 4,537 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth $80,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.